145 related articles for article (PubMed ID: 33506580)
1. Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer.
Quan Q; Zhou S; Liu Y; Yin W; Liao Q; Ren S; Zhang F; Meng Y; Mu X
J Obstet Gynaecol Res; 2021 Apr; 47(4):1527-1535. PubMed ID: 33506580
[TBL] [Abstract][Full Text] [Related]
2. Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study.
Szender JB; Emmons T; Belliotti S; Dickson D; Khan A; Morrell K; Khan ANMN; Singel KL; Mayor PC; Moysich KB; Odunsi K; Segal BH; Eng KH
Gynecol Oncol; 2017 Sep; 146(3):491-497. PubMed ID: 28624153
[TBL] [Abstract][Full Text] [Related]
3. High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer.
Wu X; Shen S; Qin J; Fei W; Fan F; Gu J; Shen T; Zhang T; Cheng X
BJOG; 2022 Nov; 129 Suppl 2(Suppl 2):40-49. PubMed ID: 36485069
[TBL] [Abstract][Full Text] [Related]
4. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
Farolfi A; Scarpi E; Greco F; Bergamini A; Longo L; Pignata S; Casanova C; Cormio G; Bologna A; Orditura M; Zavallone L; Attademo L; Gallà V; Franzese E; Pigozzi E; Loizzi V; Giorda G; Giardina D; Cioffi R; De Giorgi U
Sci Rep; 2020 Oct; 10(1):18190. PubMed ID: 33097745
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer.
Allensworth SK; Langstraat CL; Martin JR; Lemens MA; McGree ME; Weaver AL; Dowdy SC; Podratz KC; Bakkum-Gamez JN
Gynecol Oncol; 2013 Sep; 130(3):499-504. PubMed ID: 23747328
[TBL] [Abstract][Full Text] [Related]
7. Role of HER family members in predicting prognoses in epithelial ovarian cancer: a meta-analysis.
Ouyang W; Xu L; Huang Z; Guo J; Cai J; Gao X; Wang Z
Tumori; 2015; 101(6):595-602. PubMed ID: 26045112
[TBL] [Abstract][Full Text] [Related]
8. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
Yang HM; Lou G
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
[No Abstract] [Full Text] [Related]
9. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
10. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
11. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
12. In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Xu X; Dai H; Zhao Y; Wang Y; Xu X; Qian Z; Chen X
Eur J Gynaecol Oncol; 2013; 34(6):559-64. PubMed ID: 24601052
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
14. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
[TBL] [Abstract][Full Text] [Related]
15. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC).
Kolomainen DF; Daponte A; Barton DP; Pennert K; Ind TE; Bridges JE; Shepherd JH; Gore ME; Kaye SB; Riley J
Gynecol Oncol; 2012 Apr; 125(1):31-6. PubMed ID: 22082991
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of ascites in epithelial ovarian cancer.
Huang H; Li YJ; Lan CY; Huang QD; Feng YL; Huang YW; Liu JH
Neoplasma; 2013; 60(5):546-52. PubMed ID: 23790174
[TBL] [Abstract][Full Text] [Related]
18. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
19. Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
Despierre E; Moisse M; Yesilyurt B; Sehouli J; Braicu I; Mahner S; Castillo-Tong DC; Zeillinger R; Lambrechts S; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I
Gynecol Oncol; 2014 Dec; 135(3):415-22. PubMed ID: 25281495
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
